Voleon Capital Management LP Invests $443,000 in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Voleon Capital Management LP purchased a new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 55,962 shares of the company's stock, valued at approximately $443,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. PDT Partners LLC acquired a new stake in shares of Amneal Pharmaceuticals in the 4th quarter worth $627,000. Nantahala Capital Management LLC raised its position in Amneal Pharmaceuticals by 37.3% in the fourth quarter. Nantahala Capital Management LLC now owns 3,665,529 shares of the company's stock valued at $29,031,000 after purchasing an additional 995,586 shares during the period. Northern Trust Corp lifted its stake in shares of Amneal Pharmaceuticals by 9.7% in the 4th quarter. Northern Trust Corp now owns 1,777,283 shares of the company's stock valued at $14,076,000 after purchasing an additional 156,699 shares during the last quarter. Aquatic Capital Management LLC acquired a new stake in shares of Amneal Pharmaceuticals during the fourth quarter valued at about $456,000. Finally, Oxford Asset Management LLP purchased a new stake in shares of Amneal Pharmaceuticals in the 4th quarter valued at approximately $440,000. Institutional investors and hedge funds own 31.82% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on AMRX. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and lifted their price objective for the company from $9.00 to $12.00 in a research note on Monday, February 24th. Barclays raised their price target on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the company an "overweight" rating in a research report on Monday, March 3rd. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $10.80.

Amneal Pharmaceuticals Trading Down 5.4 %

Shares of AMRX stock traded down $0.43 on Monday, reaching $7.54. 2,733,660 shares of the stock were exchanged, compared to its average volume of 1,419,906. Amneal Pharmaceuticals, Inc. has a twelve month low of $6.29 and a twelve month high of $9.48. The company has a market capitalization of $2.34 billion, a price-to-earnings ratio of -11.09 and a beta of 1.17. The business's 50 day moving average price is $8.02 and its 200 day moving average price is $8.16.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last announced its quarterly earnings results on Friday, May 2nd. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.14 by $0.05. The firm had revenue of $695.42 million during the quarter, compared to the consensus estimate of $714.78 million. Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. Equities research analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current year.

Insider Activity at Amneal Pharmaceuticals

In related news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the business's stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $8.35, for a total value of $41,750,000.00. Following the transaction, the insider now owns 48,578,209 shares in the company, valued at $405,628,045.15. The trade was a 9.33 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Gautam Patel sold 80,000 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $8.90, for a total value of $712,000.00. Following the sale, the director now directly owns 1,808,886 shares of the company's stock, valued at $16,099,085.40. The trade was a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 26.56% of the company's stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.